Andy Hahn: Congrats to Ana Aparicio and team on this trial of 192 men with mCRPC

Andy Hahn, Genitourinary Medical Oncologist at MD Anderson Cancer Center, shared on X:

“Congratulations to Ana Aparicio and team on this adaptive, investigator-initiated trial of 192 men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) at Clinical Cancer Research! All men got 8 weeks of AAPA. Based on Prostate Specific Antigen (PSA) decline at 8 weeks, went on to add ipi, continue AAPA, or add cabazitaxel/carboplatin.

Aggressive Variant Prostate Cancer (AVPC) molecular signature was associated with worse response to AAPA at 8 weeks. And men who had unsatisfactory response to 8 weeks of AAPA had shorter survival, despite cabazitaxel/carboplatin.

Addition of ipilimumab to AAPA did not improve outcomes in Androgen Receptor (AR) -responsive mCRPC.

Exploratory bulk RNA Sequence in lymph node specimens identified subsets of macrophages enriched in the unsatisfactory group.”

Additional information
Source: Andy Hahn/X